UK medical and life sciences research and development under spotlight:
This article was originally published in Clinica
The strategy and management of the UK's medical and life sciences research are the subject of the House of Commons' Science and Technology Committee's first oral hearing on the work of the research council institutes. The meeting, which is open to the public and takes place in Westminster on June 28 (full details at www.parliament.uk/s&tcom), will hear evidence from Professor Julia Goodfellow, chief executive of the Biotechnology and Biological Sciences Research Council, and Professor Colin Blakemore, chief executive of the Medical Research Council. The STC last week published its report on research council support for knowledge transfer, which highlights the importance of fully engaging industry and better observing the needs of small and medium-sized enterprises (SMEs).
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.